← PFIZER (PFE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
PFIZER (PFE)
Pharmaceutical Preparations · market cap $160.0B · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09
Conference
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Pfizer (PFE) is a large-cap pharmaceutical company with about 75,000 employees and a market cap of roughly $169.8B at about $29.79 a share. Our data lists elranatamab (Phase 3, multiple myeloma) as the lead asset within a very broad pipeline across oncology, vaccines, immunology and anti-infectives. The near-term setup is Q3 earnings on 2026-11-03, followed by a cluster of estimated-date readouts in November and December, three of them rated 9/10 importance.
The catalyst path
- 2026-11-09Conferenceimp 2/10
- 2026-11-12 (est.)Phase 2 · PF-07275315imp 7/10
- 2026-11-15 (est.)Phase 2 · Pertuzumabimp 7/10
- 2026-11-29 (est.)Phase 3 · Rimegepantimp 9/10
- 2026-12-01 (est.)Phase 2 · elranatamabimp 7/10
- 2026-12-02 (est.)Phase 3 · Ritlecitinib higher doseimp 9/10
- 2026-12-04 (est.)Phase 3 · VLA15imp 9/10
- 2026-12-04 (est.)Phase 2 · Sunitinibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| brentuximab vedotin | Phase 3 | Lymphoma, B-Cell |
| DVS-233 SR (desvenlafaxine sustained release) | Phase 3 | Major Depressive Disorder |
| PF-08653945 | Phase 2 | Overweight |
| Insulin Lispro | Phase 3 | Diabetes Mellitus |
| Cyclosporine A | Phase 3 | Renal Transplantation |
| PF-06826647 | Phase 2 | Psoriasis |
| 13 valent pneumococcal conjugate vaccine with Polysorbate 80 | Phase 3 | Vaccines, Pneumococcal |
| Meropenem | Phase 3 | Complicated Intra-abdominal Infections |
| MET097 | Phase 3 | Obesity |
| RSVpreF (Group 1) | Phase 3 | RSV |
| Imipenem-cilastatin | Phase 3 | Skin Infection |
| Diclofenac | Phase 3 | Spondylitis, Ankylosing |
| PF-07850327, ARV-471, vepdegestrant | Phase 2 | Locally Advanced or Metastatic ER+ HER2- Breast Cancer |
| CP-690-550 | Phase 2 | Arthritis, Rheumatoid |
| SU-011,248 | Phase 2 | Kidney Neoplasms |
| Pediacel | Phase 3 | Vaccines, Pneumococcal |
| Pemetrexed/Cisplatin | Phase 3 | NSCLC (Non-small Cell Lung Cancer) |
| Conventional amphotericin B | Phase 3 | Candidiasis |
| Multivalent Pneumococcal Vaccine - Formulation 1 | Phase 2 | Pneumococcal Disease |
| SU011248, Sutent | Phase 2 | Papillary Thyroid Cancer |
Price & technical context
3-month
+11.7%
6-month
+12.8%
12-month
+23.0%
52-wk range
$23.67–$30.79
vs 50-day MA
+4.1%
vs 200-day MA
+11.1%
Realized vol
22.0%
Max drawdown
-27.2%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PFE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.